ASSOCIATION TYPE 2 DIABETES MELLITUS AND ALZHEIMER DISEASE: A SYSTEMATIC REVIEW
Keywords:
Alzheimer Disease, Genomic, Neurobehaviour, Type 2 Diabetes MellitusAbstract
The International Diabetes Federation (IDF) reports that diabetes affects one in ten people throughout the world, and that insulin-resistant type 2 diabetes mellitus (T2DM) accounts for 90 percent of all cases of diabetes. According to findings from epidemiology research, the pathophysiology and clinical patterns of Alzheimer's disease and type 2 diabetes are similar. Insulin resistance is a hallmark of both illnesses. The pathogenesis differentiates between inflammatory, metabolic, and zinc-deficient variants of the condition. Alzheimer's disease is associated with both type 2 diabetes and prediabetes, often known as metabolic syndrome. Due to the fact that Alzheimer's disease shares many pathophysiological similarities with diabetes, it is sometimes referred to as type 3 diabetes. A primary focus of dementia research is insulin resistance, which impairs cognitive function and contributes to the development of dementia. IGF has an effect on cognition as well. The chance of acquiring T2DM rises with age, much like the risk of developing Alzheimer's disease, and T2DM also raises the risk of developing dementia in general, specifically Alzheimer's disease. Both T2DM and AD are chronic and complex diseases, and both show evidence that oxidative stress and inflammation play a role in the progression of the diseases. Despite the fact that T2DM is primarily a peripheral disorder and AD is a disease of the central nervous system, the two diseases share some similarities.
References
Redulla R. Reminiscence therapy for dementia. Issues Ment Health Nurs. 2020;41(3):265–6.
Yang S-H. Cellular and Molecular Mediators of Neuroinflammation in Alzheimer Disease. Int Neurourol J [Internet] 2019 Nov 30;23(Suppl 2):S54-62. Available from: https://doi.org/10.5213/inj.1938184.092
Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besançon S, et al. Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2020;162:108072.
Chen Y, Yu Q, Gong C-X. Molecular connection between diabetes and dementia. Diabetes Mellit A risk factor Alzheimer’s Dis. 2019;103–31.
Kubis-Kubiak AM, Rorbach-Dolata A, Piwowar A. Crucial players in Alzheimer’s disease and diabetes mellitus: Friends or foes? Mech Ageing Dev. 2019;181:7–21.
Tumminia A, Vinciguerra F, Parisi M, Frittitta L. Type 2 Diabetes Mellitus and Alzheimer’s Disease: Role of Insulin Signalling and Therapeutic Implications. Int J Mol Sci. 2018 Oct;19(11).
Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: A meta‐analysis of prospective observational studies. J Diabetes Investig. 2013;4(6):640–50.
Rorbach-Dolata A, Piwowar A. Neurometabolic evidence supporting the hypothesis of increased incidence of type 3 diabetes mellitus in the 21st century. Biomed Res Int. 2019;2019.
Peña-Bautista C, Baquero M, Vento M, Cháfer-Pericás C. Omics-based biomarkers for the early Alzheimer disease diagnosis and reliable therapeutic targets development. Curr Neuropharmacol. 2019;17(7):630–47.
Abdulwahab RA, Alaiya A, Shinwari Z, Allaith AAA, Giha HA. LC‑MS/MS proteomic analysis revealed novel associations of 37 proteins with T2DM and notable upregulation of immunoglobulins. Int J Mol Med. 2019;43(5):2118–32.
Huth C, von Toerne C, Schederecker F, de las Heras Gala T, Herder C, Kronenberg F, et al. Protein markers and risk of type 2 diabetes and prediabetes: a targeted proteomics approach in the KORA F4/FF4 study. Eur J Epidemiol
[Internet] 2019;34(4):409–22. Available from: https://doi.org/10.1007/s10654-018-0475-8
Dey KK, Wang H, Niu M, Bai B, Wang X, Li Y, et al. Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer’s disease. Clin Proteomics [Internet] 2019;16(1):16. Available from: https://doi.org/10.1186/s12014-019-9237-1
Li D, Huang F, Zhao Y, Villata PW, Griffin TJ, Zhang L, et al. Plasma lipoproteome in Alzheimer’s disease: a proofof-concept study. Clin Proteomics [Internet] 2018;15(1):31. Available from: https://doi.org/10.1186/s12014-0189207-z
Park J-C, Han S-H, Lee H, Jeong H, Byun MS, Bae J, et al. Prognostic plasma protein panel for Aβ deposition in the brain in Alzheimer’s disease. Prog Neurobiol [Internet] 2019;183:101690. Available from: https://www.sciencedirect.com/science/article/pii/S0301008219301194
Fauci AS, Jameson JL, Kasper D, et al. Harrison’s Principles of Internal Medicine 19th Edition. New York: McGrawHill Education; 2018.
Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799–806.
Hölscher C. Diabetes as a risk factor for Alzheimer’s disease: insulin signalling impairment in the brain as an alternative model of Alzheimer’s disease. Biochem Soc Trans. 2011 Aug;39(4):891–7.
Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer’s disease: implications for treatment. CNS Drugs. 2003;17(1):27–45.
Al Kindi MA, Chataway TK, Gilada GA, Jackson MW, Goldblatt FM, Walker JG, et al. Serum SmD autoantibody proteomes are clonally restricted and share variable-region peptides. J Autoimmun. 2015;57:77–81.
Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol. 1999 Dec;26(3–4):259–65.
Thiel S. Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol Immunol. 2007;44(16):3875–88.
S Roriz-Filho J, Sá-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves MLF, et al. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta. 2009 May;1792(5):432–43.
Halmos T, Suba I. [Alzheimer’s disease and diabetes - the common pathogenesis] Neuropsychopharmacol Hungarica a Magy Pszichofarmakologiai Egyes lapja = Off J Hungarian Assoc Psychopharmacol. 2016 Mar;18(1):5–19.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
